Application of lipid microspheres for the treatment of cancer

Advanced Drug Delivery Reviews

Volumn 20, Issue 2-3, 1996, Pages 209-219

  Takenaga, Mitsuko ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

1,3 bis(2 chioroethyl) 1 nitrosourea; Chemotherapy; Drug delivery system; L1210 leukemia; Lipid microspheres; Lipid nanospheres

Indexed keywords

AROMATIC COMPOUNDS; BLOOD; CELLS; DISEASES; DRUG DOSAGE; DRUG INTERACTIONS; LIPIDS; ONCOLOGY; PATIENT TREATMENT; TOXICITY;

ANTITUMOR AGENTS; BISCHLOROETHYL NITROSOUREA; CHEMOTHERAPY; EGG YOLK LECITHIN; LEUKEMIA; LIPID MICROSPHERES; LIPID NANOSPHERES; LIPOPHILIC CHEMOTHERAPY AGENTS; RETICULOENDOTHELIAL SYSTEMS; SOY BEAN OIL SOLUTION;

DRUG THERAPY;

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; DRUG CARRIER; LIPID; MICROSPHERE; NANOPARTICLE; PHOSPHATIDYLCHOLINE; RADIOISOTOPE; SOYBEAN OIL; TRIOLEIN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER GRAFT; CANCER THERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG UPTAKE; ENCAPSULATION; FEMALE; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA L 1210; LIPOPHILICITY; MOUSE; NONHUMAN; PARTICLE SIZE; PHARMACEUTICS; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW;

EID: 0030602779     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(95)00124-P     Document Type: Review

References (35)

1. [1] Papahadjopoulos, D. (1978) Liposomes and their uses in biology and medicine. Ann. N.Y. Acad. Sci. 308, 1-462.
2. [2] Kato, T. (1983) Encapsulated drugs in targeted cancer therapy. In: S.R. Bruck (Ed), Controlled Drug Delivery, CRC Press, Boca Raton, FL, pp. 189-195.
3. [3] Konno, H., Suzuki, H., Tadakuma, T., Kumai, K., Yasuda, T., Kubota, T., Ohta S., Nagaike, K., Hosokawa, S., Ishibiki, K., Abe, O. and Saito, K. (1987) Antitumor effect of adriamycin-entrapped liposomes conjugated with antihuman α-fetoprotein monoclonal antibody. Cancer Res. 47, 4471-4477.
4. [4] Matthay, K.K., Abai, A.M., Cobb, S., Hong, K., Papahadjopoulos, D. and Straubinger, R. (1980) Role of ligand and antibody-directed endocytosis of liposomes by human T-leukemia cells. Cancer Res. 49, 4879-4886.
5. [5] Loeffler, C.M., Platt, J.L., Manderson, P., Katsanis, E., Ochoa, J.B., Urba, W.J., Longo, D.L., Lenard, A.S. and Ochoa, A.C. (1991) Antitumor effect of interleukin-2 liposomes and anti-CD3-stimulated T cells against murine MCA-38 hepatic metastasis. Cancer Res. 51, 2127-2132.
6. [6] Mayer, L.D., Tai, L.C.L., Ko, D.S.C., Masin, D., Ginsberg, R.S., Cullis, P.R. and Balley, M.B. (1989) Influence of vesicle size, lipid composition and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 49, 5922-5930.
7. [7] Maruyama, K., Kennel, S.J. and Huang, L. (1990) Lipid composition is important for highly efficient target binding and retention of immunoliposomes. Proc. Natl. Acad. Sci. USA 87, 5744-5748.
8. [8] Dinney, C.P.N., Utsugi, T., Fidler, I.J., von Eschenbach, A.C. and Killion, J.J. (1992) Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activators GCP 31362 or CGP 19853A in combination with interleukin-2 or gammma-interferon. Cancer Res. 52, 1155-1161.
9. [9] Bono, V.H. (1976) Review of mechanism of action studies of the nitrosoureas. Cancer Treat. Rep. 60, 699-707.
10. [10] Carter, S.K. (1981) Design of clinical trials with nitrosoureas. In: A.W. Prestayko, S.T. Crooke, L.H. Baker, S.K. Caster and P.S. Schein (Eds), Nitrosoureas, Current Status and New Developments. Academic Press, New York, NY, pp. 411-416.
11. [11] Wasserman, T.H. (1976) The nitrosoureas: an outline of clinical schedules and toxic effects. Cancer Treat. Rep. 60, 709-711.
12. [12] Kanamaru, R., Asamura, M., Sato, H., Saito, S., Wakui, A. and Saito, T., (1980) Studies on the mechanism of action of ACNU, 1-(4-amino-2-methylpyrimidine-5-yl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride: effect on cultured HeLa S3 cells. Tohoku J. Exp. Med. 132, 431-441.
13. [13] Sekido, S., Ninomiya, K. and Iwasaki, M. (1979) Biologic activity of MCNU: a new antitumor agent. Cancer Treat. Rep. 63, 961-970.
14. [14] Gabizon, A., Price, D.C., Huberty, J.B., Resalier, R.S. and Papahadjopoulos, D. (1990) Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: Biodistribution and imaging studies. Cancer Res. 50, 6731-6378.
15. [15] Mizushima, Y., Hammano, T. and Yokoyama, K. (1982) Tissue distribution and anti-inflammatory activity of corticoids incorporated in lipid emulsion. Ann. Rheum. Dis. 41, 263-267.
16. [16] Watanabe, Y., Okura, A., Naito, K. and Kobayashi, M. (1988) Murine liver metastasis model using L5178Y-ML lymphoma and the effect of antitumor agents on the metastasis. Jpn. J. Cancer Res. 79, 1208-1216.
17. 1 incorporated in lipid microspheres in peripheral vascular disease secondary to connective tissue disorders. J. Rheumatol. 14, 97-101.
18. [18] Mizushima, Y. (1991) Lipo-prostaglandin preparations (review) Prostaglandins Leukotrienes Essent. Fatty Acids 42, 1-6.
19. [19] Karalovic, R.C., Andrew, M., Zepp, E. and Cenedella, R.J. (1977) Studies of the mechanism of carcass fat depletion in experimental cancer. Eur. J. Cancer 13, 1071-1079.
20. [20] Chernick, S.S., Spooner, P.M., Garrison, M.M. and Scow, R.O. (1986) Effect of epinephrine and other lipolytic agents on intracellular lipolysis and lipoprotein activity in 3T3L1 adipocyte. J. Lipid Res. 27, 286-294.
21. [21] Noguchi, Y., Vydelingum, N.A., Youners, R.N., Fried, S.K. and Brenan, M.F. (1991) Tumor-induced alterations in tissue lipoprotein lipase and mRNA levels. Cancer Res. 51, 863-869.
22. [22] Shoji, Y., Mizushima, Y. and Kametani, T. (1986) Affinity of lipid microspheres for MM-46 tumor cells. J. Pharm. Soc. Jpn. 106, 605-608 (in Japanese).
23. [23] Konno, T., Maeda, H. and Iwai, K.(1983) Effect of arterial administration of high-molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur. J. Cancer Clin. Oncol. 19, 1053-1065.
24. [24] Hayashi, Y., Fukushima, S., Kishimoto, S., Kawaguchi, T., Numata, M., Isoda, Y., Hirano, J. and Nakano, M. (1992) Antitumor effects of free polyunsaturated fatty acids in an oily lymphographic agent following intrahepatic arterial administration to a rabbit bearing VX-2 tumor. Cancer Res. 52, 400-405.
25. [25] Noseda, A., Berens, M.E., White, J.G. and Modest, E.J. (1988) In vitro antiproliferative activity of combination of ether lipid analogues and DNA-interactive agents against human tumor cells. Cancer Res. 48, 1788-1791.
26. [26] Chabot, M.C., Wykie, R.L., Modest, E.J. and Daniel, L.W. (1989) Correlation of ether lipid content of human leukemia cell lines and their susceptibility to 1-o-octa-decyl-2-o-methyl-rac. glycero-3-phosphocholine. Cancer Res. 49, 4441-4445.
27. [27] Figiwara, K., Modest, E.J., Welander, C.E. and Wallen, C.A. (1989) Cytotoxic interactions of heat and ether lipid analogues in human ovarian carcinoma cells. Cancer Res. 49, 6285-6289.
28. [28] Beck, S.A., Smith, K.L. and Tisdale, M.J. (1991) Anticachectic and antitumor effect of eicosapentadecanoic acid and its effect on protein turnover. Cancer Res. 51, 6089-6093.
29. [29] Jett, M., Chudzik, J., Alving, C.R. and Stanacev, N.Z. (1985) Metabolic fate of liposomal phosphatidylinositol in murine tumor cells: implications for the mechanism of tumor cell cytotoxicity. Cancer Res. 45, 4810-4815.
30. [30] Carter, S.K., Shabel, F.M., Broder, L.E. and Johnston, T.P. (1972) 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) and other nitrosoureas in cancer treatment: a review. Adv. Cancer Res. 16, 273-332.
31. 1 prodrug for targeting therapy. J. Control. Rel. 20, 37-46.
32. 1 incorporated in lipid microspheres in the treatment of peripheral vascular diseases and diabetic neuropathy. Drug Exp. Clin. Res. 12, 681-685.
33. [33] Rutman, R.J., Ritter, C.A., Avadhani, N.G. and Hansel, J. (1976) Liposomal potentiation of the antitumor activity of alkylating drugs. Cancer Treat. Rep. 60, 617-618.
34. [34] Inaba, M., Yoshida, N. and Tsukagoshi, S. (1981) Preferential action of liposome-entrapped 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on lung metastasis of Lewis lung carcinoma as compared with the free drug. Gann 72, 341-345.
35. [35] Takenaga, M., Igarashi, R., Tsuji, H. and Mizushima, Y. (1993) Enhanced antitumor activity and reduced toxicity of 1,3-bis-2-chloroethyl-1-nitrosourea administered in lipid microspheres to tumor-bearing mice. Jpn. J. Cancer Res. 84, 1078-1085.